

Generation and publishing of statistical output for eCTD's at Novo Nordisk

PhUSE SDE, Copenhagen 8. marts 2011

Mikkel Traun,
CDW Operations
Novo Nordisk A/S

mt@novonordisk.com



Generation and publishing of statistical output for eCTD's at Novo Nordisk

- At NN we have a process for **specification, planning, implementing** and **publishing** of statistical output for section 14 of the ICTR in the eCTD format
- This process and tools have been evolved over the years and we see it as part of our best practices
- A key element is a XML tagging of metadata for each output file
- And we continuously have ideas and visions for improvements

Electronic Common Technical Document (eCTD)



Sample eCTD

Liquent InSight* Viewer

Product List > Application List > Sequence List >

Quick Search [] Go

THOMSON REUTERS

Sequence (0000)

Outline Numbers

- Clinical Study Reports
 - Clinical Study Reports
 - 2 Tabular Listing of All Clinical Studies
 - 3 Clinical Study Reports
 - 5.3.1 Reports of Biopharmaceutic Studies
 - 5.3.2 Reports of Studies Pertinent To Pharmacokinetics
 - 5.3.3 Reports of Human Pharmacokinetics PK Studies
 - 5.3.4 Reports of Human Pharmacodynamics Pd Studies
 - 5.3.4.1 Healthy Subject Pd and PK Pd Study Reports
 - Study Report NN
 - Synopsis (new)
 - A Thorough QTC Evaluation of the Effect (new)
 - Protocol and Protocol Amendments (new)
 - Sample Case Report Form (new)
 - List of IECs or IRBs (new)
 - Description of Investigators and Sites (new)
 - Signatures of Principal or Coordinating Investigator
 - Listing of Patients Receiving Test Drug(s)
 - Randomisation Scheme (new)
 - Audit Certificates or Similar Documentation
 - Documentation of Statistical Methods and Analysis
 - Documentation of Inter-laboratory Standards
 - Publications Based on the Study (new)
 - Publications Referenced in the Study Report
 - Discontinued Patients Listing (new)
 - Protocol Deviation Listing (new)
 - Patients Excluded from Efficacy Analysis
 - Demographic Data Listing (new)
 - Compliance and/or Drug Concentration Data
 - Individual Efficacy Response Data Listing
 - Adverse Event Listings (new)
 - Individual Laboratory Measurements Listing
 - Case Report Forms for Deaths, Other Serious Adverse Events
 - Other CRFs submitted (new)
 - Individual Patient Data Listings (new)
- 5.3.4.2 Patient Pd and PK Pd Study Reports
- 5.3.5 Reports of Efficacy and Safety Studies (Detailed)
- 4 Literature References

Properties / History File View Comments

7 / 351 100%

Find

Bookmarks

- Graphs Referred to but not Included in the Text
- 14.1 Demographic Data
 - Table 14.1-1 Demography and Screening Data (All)
 - Table 14.1-1-1 Demography and Screening Data (Safety)
 - Table 14.1-1-2 Demography and Screening Data (Per Protocol Population)
 - Table 14.1-2 Medical History/Concomitant Illness (All)
 - Table 14.1-2-1 Medical History/Concomitant Illness (Safety)
 - Table 14.1-2-2 Medical History/Concomitant Illness (Per Protocol Population)
 - Table 14.1-3 Concomitant Medications - Safety Population
 - Table 14.1-3-1 Concomitant Medications - Per Protocol Population
 - Table 14.1-4 Laboratory Data - Urinalysis at Screening - All Randomized Subjects
 - Table 14.1-4-1 Laboratory Data - Urinalysis at Screening - Safety Population
 - Table 14.1-4-2 Laboratory Data - Urinalysis at Screening - Per Protocol Population

13 Discussion and Overall Conclusions 78

14 Tables, Figures and Graphs Referred to but not Included in the Text 79

14.1 Demographic Data 79

Table 14.1-1 Demography and Screening Data (All) 80

Table 14.1-1-1 Demography and Screening Data (Safety) 82

Table 14.1-1-2 Demography and Screening Data (Per Protocol Population) 84

Table 14.1-2 Medical History/Concomitant Illness (All) 86

Table 14.1-2-1 Medical History/Concomitant Illness (Safety) 91

Table 14.1-2-2 Medical History/Concomitant Illness (Per Protocol Population) 96

Table 14.1-3 Concomitant Medications - Safety Population 100

Table 14.1-3-1 Concomitant Medications - Per Protocol Population 101

Table 14.1-4 Laboratory Data - Urinalysis at Screening - All Randomized Subjects 102

Table 14.1-4-1 Laboratory Data - Urinalysis at Screening - Safety Population 104

Table 14.1-4-2 Laboratory Data - Urinalysis at Screening - Per Protocol Population 106


14.2 Efficacy Data 79


Table 14.2-1 Subject Disposition 108

Table 14.2-2 Study Treatment Status 109

Local intranet

Process from specification to eCTD output





- The Project Statistical Programming Specification (**PPS**) holds the **standard Template Specification**
- The **Protocol** holds the SAP section and Trial Metadata specification
- The **Project Programming Plan** holds linkage between **standard templates** and use of **standard programs** and ID's
- The **SPS** holds detailed **specification** of all **output** that are to be part of the ICTR in a **SPS Template Section**

Sample SPS Template Specification

template_section_14_1_nn1250_3672_v8.doc - Microsoft Word

File Edit View Insert Format Tools Table Xref Manager Window UserData Help Style Template Menu

Table 2 Subject Disposition by Country – Summary


	Treatment1 N (%)	Treatment2 N (%)	Comparator N (%)	Total N (%)
Australia				
Screened				xx
Randomized	xx (100.0)	xx (100.0)	xx (100.0)	xx (100.0)
Exposed	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Completed Trial	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Full Analysis Set	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
PP Analysis Set	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Safety Analysis Set	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Germany				
Screened				xx
Randomized	xx (100.0)	xx (100.0)	xx (100.0)	xx (100.0)
Exposed	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Completed Trial	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Full Analysis Set	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
PP Analysis Set	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Safety Analysis Set	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)

N: Number of subjects
%: Proportion of randomised subjects

Notes

- Special CDW table
- Include all counties
- Percentages are calculated relative to number of randomised subjects
- Output name: *t_dispos_country_sum*


Page 5 Sec 1 5/17 At 10.7 cm Ln 19 Col 83 REC TRK EXT OVR English (U.K)



Prog.
Plan


- Specify each **output** and **program** or **standard program** producing the output
- Tracks validation status, who, when, etc.

Status overview in ProgPlan



Specification**Planning****Implement-
ation****Publishing**


- SAS programs calls %init_start macro for generation of output
- SAS output directed to file in specified format
- XML file generated with metadata definition of output
 - Document section
 - Title
 - Sequence ID



SAS program call %init_start

```
%init_start_v04(  
    outtype           = Table  
    ,level            = 2  
    ,id               = 1420100  
    ,document         = 14_2  
    ,exp_dataset      =  
    ,pgmname          = t_subj_dis.sas  
    ,paper_orientation = land  
    ,font_size        = 9  
    ,output_format    =  
    ,title_text       = Subject disposition by Treatment  
    ,data             =  
    ,abbrev_cols      = row_lb  
    ,usr_footnote     =  
    ,usr_footnote_delim = ~  
    ,inc_auto_footnotes = yes  
    ,auto_filename    = yes  
    ,pre_output_name  =  
    ,post_output_name = t_subj_dis_all  
);
```


SAS Program makes output and XML




```
<?xml version="1.0" encoding="windows-1252" ?>
- <StatOutput>
  <OutputType>Table</OutputType>
  <Id>1420100</Id>
  <Project>CDWtest</Project>
  <Trial>current</Trial>
  <Instance>stats</Instance>
  <Level>2</Level>
- <Title>
  <Title1>Subject disposition by Treatment</Title1>
  <Title2 />
  <Title3 />
  <Title4 />
</Title>
<TitleLines>1</TitleLines>
<FontSize>9</FontSize>
<Paper>land</Paper>
<Document>14_2</Document>
<FileName>t_subj_dis_all.txt</FileName>
<HtmlFileName />
<RtfFileName />
<FigureDataSet />
<ProgramName>t_subj_dis.sas</ProgramName>
<TimeStamp>05OCT10 - 13:01</TimeStamp>
</StatOutput>
```


Specification**Planning****Implement-
ation****Publishing**

- SAS programs calls %init_start macro for generation of output
- SAS output directed to file in specified format
- XML file generated with metadata definition of output
 - Document section
 - Title
 - Sequence ID
- Automatic assembling of output files into section documents
- Automatic table numbering
- Automatic TOC and local bookmarks





- Integrate section documents into master documents
- Master TOC, bookmarks, etc.
- Volumes and page numbering



Sample NN eCTD

Liquent InSight* Viewer

Product List > Application List > Sequence List >

Quick Search Go

THOMSON REUTERS

Sequence (0000)

Properties / History File View Comments

7 / 351 100%

Find

Bookmarks

Graphs Referred to but not Included in the Text

14.1 Demographic Data

Table 14.1-1-1 Demography and Screening Data (All)

Table 14.1-1-1 Demography and Screening Data (Safety)

Table 14.1-1-2 Demography and Screening Data (Per

Table 14.1-2 Medical History/Concomitant Illness (All)

Table 14.1-2-1 Medical History/Concomitant Illness (Safety)

Table 14.1-2-2 Medical History/Concomitant Illness (Per-Protocol Population)

Table 14.1-3 Concomitant Medications - Safety Population

Table 14.1-3-1 Concomitant Medications - Per-Protocol Population

Table 14.1-4 Laboratory Data - Urinalysis at Screening - All Randomized Subjects

Table 14.1-4-1 Laboratory Data - Urinalysis at Screening - Safety Population

Table 14.1-4-2 Laboratory Data - Urinalysis at Screening - Per Protocol Population

Table 14.1-4-1 Laboratory Data - Urinalysis at Screening - All Randomized

Table 14.1-4-1 Laboratory Data - Urinalysis at Screening - Safety

13 Discussion and Overall Conclusions 78

14 Tables, Figures and Graphs Referred to but not Included in the Text 79

14.1 Demographic Data 79

Table 14.1-1 Demography and Screening Data (All 80

Table 14.1-1-1 Demography and Screening Data (Safety 82

Table 14.1-1-2 Demography and Screening Data (Per 84

Table 14.1-2 Medical History/Concomitant Illness (All 86

Table 14.1-2-1 Medical History/Concomitant Illness (Safety 91

Table 14.1-2-2 Medical History/Concomitant Illness (Per-Protocol Population) 96

Table 14.1-3 Concomitant Medications - Safety Population 100

Table 14.1-3-1 Concomitant Medications - Per-Protocol Population 101

Table 14.1-4 Laboratory Data - Urinalysis at Screening - All Randomized Subjects 102

Table 14.1-4-1 Laboratory Data - Urinalysis at Screening - Safety Population 104

Table 14.1-4-2 Laboratory Data - Urinalysis at Screening - Per Protocol Population 106


14.2 Efficacy Data 79

Table 14.2-1 Subject Disposition 108

Table 14.2-2 Study Treatment Status 109

Local intranet

Process from specification to eCTD output



Benefit and Issues in current process

- Benefits
 - Standard programs have been made generic and to a large extent metadata driven
 - Assembling of individual output files into document sections
- Issues
 - Too much flexibility in standard elements
 - Manual process of making trial SPS from 'P'SPS
 - Too much input is needed to call standard programs
- Improvements to the Trial SPS process is needed

Visions and ideas for improvements

